McKesson (MCK) stock surged 41% between August 2025 and February 2026, driven by strong oncology segment growth, accelerated core business performance, and enhanced profitability. The company’s strategic focus on high-growth North American markets, improved earnings per share, and robust free cash flow generation contributed significantly to investor confidence. However, potential future challenges include a recent decline in operating cash flow and margin pressure from the Inflation Reduction Act.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Why McKesson Stock Jumped 40%?
McKesson (MCK) stock surged 41% between August 2025 and February 2026, driven by strong oncology segment growth, accelerated core business performance, and enhanced profitability. The company’s strategic focus on high-growth North American markets, improved earnings per share, and robust free cash flow generation contributed significantly to investor confidence. However, potential future challenges include a recent decline in operating cash flow and margin pressure from the Inflation Reduction Act.